興科蓉醫藥：2022中期報告.pdf

1、中期報告2022Interim ReportSinco Pharmaceuticals Holdings Limited 兴科蓉医药控股有限公司2022 Interim Report 中期報告Contents目錄2Corporate Information公司資料4Financial Highlights財務摘要6Corporate Profile公司簡介7Management Discussion and Analysis管理層討論及分析23Other Information其他資料31Interim Condensed Consolidated Statement of Profit or

2、 Loss and Other Comprehensive Income中期簡明綜合損益及其他全面收益表32Interim Condensed Consolidated Statement of Financial Position中期簡明綜合財務狀況表34Interim Condensed Consolidated Statement of Changes in Equity中期簡明綜合權益變動表35Interim Condensed Consolidated Statement of Cash Flows中期簡明綜合現金流量表37Notes to Interim Condensed Fin

3、ancial Information中期簡明財務資料附註66Definitions釋義Corporate Information公司資料2Sinco Pharmaceuticals Holdings Limited Interim Report 2022BOARD OF DIRECTORSExecutive DirectorMr.Huang Xiangbin(Chairman and Co-Chief Executive Officer)Independent Non-executive DirectorsMr.Lau Ying KitMr.Liu WenfangMr.Wang QingMr.

4、Bai ZhizhongAUDIT COMMITTEEMr.Lau Ying Kit(Chairman)Mr.Liu WenfangMr.Wang QingMr.Bai ZhizhongREMUNERATION COMMITTEEMr.Wang Qing(Chairman)Mr.Liu WenfangMr.Bai ZhizhongNOMINATION COMMITTEEMr.Huang Xiangbin(Chairman)Mr.Liu WenfangMr.Lau Ying KitINTERNAL CONTROL AND CORPORATE GOVERNANCE COMMITTEEMr.Lau

5、Ying Kit(Chairman)Mr.Wang QingMr.Liu WenfangMr.Bai ZhizhongAUTHORISED REPRESENTATIVESMr.Huang XiangbinMr.Li Kin WaiJOINT COMPANY SECRETARIESMs.Peng YunluMr.Li Kin WaiREGISTERED OFFICEPO Box 309Ugland HouseGrand Cayman,KY1-1104Cayman Islands董事會執行董事黃祥彬先生（主席兼聯席行政總裁）獨立非執行董事劉英傑先生劉文芳先生汪晴先生白志中先生審核委員會劉英傑先生（

6、主席）劉文芳先生汪晴先生白志中先生薪酬委員會汪晴先生（主席）劉文芳先生白志中先生提名委員會黃祥彬先生（主席）劉文芳先生劉英傑先生內部控制及企業管治委員會劉英傑先生（主席）汪晴先生劉文芳先生白志中先生授權代表黃祥彬先生李健威先生聯席公司秘書彭雲璐女士李健威先生註冊辦事處PO Box 309Ugland HouseGrand Cayman,KY1-1104Cayman Islands32022 中期報告 興科蓉醫藥控股有限公司Corporate Information(Continued)公司資料（續）CORPORATE HEADQUARTERSE5-1805,Global CentreNo.17